Business
Pacira Receives Notice of Allowance for New Patent Covering EXPAREL Composition
-- Patent eligible for Orange Book listing will provide additional protection into 2041 -- TAMPA, Fla., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences,
About this update from Pacira Biosciences, Inc.
[{"type":"text","content":"-- Patent eligible for Orange Book listing will provide additional protection into 2041 -- TAMPA, Fla., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a U.S. Patent Application claiming chemical composition of EXPAREL® (bupivacaine liposome injectable suspension). After issuance, Pacira will submit this patent for listing in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). Patents that are eligible for Orange Book listing are those that have claims covering the active ingredient, the drug product (formulation and composition) or the approved method of use. The company also received a Notice of Allowance from the USPTO for a separate patent application claiming a novel EXPAREL manufacturing process. The EXPAREL manufacturing processes are highly specific and a core competency proprietary to Pacira. A Notice of Allowance is issued after the USPTO concludes a substantive examination of the patent application and determines that the prosecution on the merits of a patent has been completed. The USPTO then grants the patent upon payment of the patent issuance fee. The composition patent and the manufacturing process patent will each have an expiration date of January 22, 2041. “We are pleased to enhance our intellectual property protection for EXPAREL with two new patents, including another Orange Book eligible product composition patent,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences. “Our comprehensive patent strategy is building multiple layers of protection around EXPAREL, with what we believe to be additional Orange Book listable patents forthcoming to further secure EXPAREL from would-be competitors. We believe our strong and growing patent estate, our extensive manufacturing expertise, and the FDA’s rigorous regulatory criteria for proving bioequivalence, collectively provide significant barriers to entry that leave us highly confident in EXPAREL market leadership across a wide range of local and regional procedures for adult and pediatric patients.” About Pacira BioSciences Pacira BioSciences, Inc. (Nasdaq: PCRX) is ...